Here is what I would like to see by the end of March 2013:
1) A PR that announces the launch of Naltrexone including the official opening of Elite's 2nd facility. 2) An ECR PR that the Lodrane 24 products have been allowed back on the market. 3) A new financing deal based in part on positive BE studies related to Elite's Abuse Resistant Tech. 4) A PR related to quarterly earnings that says Elite is generating a profit. 5) The USPTO approval of the second half of Elite's Eli 216 patent.
Now given how long I have been holding shares...I am likely to see about half of what I would be hoping for. So when push comes to shove I'll take #1 and #3.